| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA842: Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated) |
|
Medicine details |
|
| Medicine name | tisagenlecleucel (Kymriah®) |
| Formulation | intravenous infusion |
| Reference number | 4473 |
| Indication | Treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy |
| Company | Novartis Oncology |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/04/2022 |
| NICE guidance | TA842: Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated) |